Gujarat Terce Laboratories Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd is trading at 32.50 as of 19 April 2026, with a FY2026-2027 high of 68.4 and low of 29.0. The stock is currently near its 52-week low. Market cap stands at 25.3 Cr..

Q: Is Gujarat Terce Laboratories Ltd financially healthy?

Key indicators: ROCE of 41.4 % indicates efficient capital utilization. Dividend yield is 0.00 %.

Q: Is Gujarat Terce Laboratories Ltd profitable and how is the profit trend?

Gujarat Terce Laboratories Ltd reported a net profit of -1 Cr in Mar 2025 on revenue of 50 Cr. Compared to 1 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹18.05Overvalued by 44.46%vs CMP ₹32.50

P/E (15.0) × ROE (14.6%) × BV (₹10.10) × DY (2.00%)

Defaults: P/E=15

₹24.05Overvalued by 26.00%vs CMP ₹32.50

MoS: -35.1% (Negative)Confidence: 33/100 (Low)Models: 1 Under, 1 Fair, 2 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹13.73	39%	Over (-57.8%)
Net Asset Value	Assets	₹10.07	24%	Over (-69%)
EV/EBITDA	Enterprise	₹54.08	20%	Under (+66.4%)
Revenue Multiple	Revenue	₹32.24	18%	Fair (-0.8%)
Consensus (4 models)		₹24.05	100%	Overvalued

Key Drivers: EPS CAGR -23.9% drags value — could be higher if earnings stabilize. | Wide model spread (₹10–₹54) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -23.9% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

Gujarat Terce Laboratories Ltd scores 59/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health58/100 · Moderate

ROCE 41.4% ExcellentROE 14.6% GoodD/E 0.59 ModerateInterest Coverage 0.0x RiskyProfitable 2/5 years Inconsistent

Smart Money60/100 · Moderate

Promoter increased by 3.00% Positive

Earnings Quality75/100 · Strong

OPM expanding (-1% → 5%) ImprovingWorking capital: -14 days (improving) Efficient

Quarterly Momentum40/100 · Moderate

Revenue (4Q): -3% YoY FlatProfit (4Q): -143% YoY Declining

Industry Rank60/100 · Moderate

ROCE 41.4% vs industry 16.4% Above peers3Y sales CAGR: 8% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:44 am

Market Cap	25.3 Cr.
Current Price	32.5
Intrinsic Value	₹24.05
High / Low	68.4/29.0
Stock P/E
Book Value	10.1
Dividend Yield	0.00 %
ROCE	41.4 %
ROE	14.6 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Gujarat Terce Laboratories Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	106 Cr.	84.2	137/76.0	21.9	49.6	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.15 Cr.	1.65	3.17/1.57		0.33	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,692 Cr.	247	479/222	56.3	24.3	0.27 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	25.3 Cr.	32.5	68.4/29.0		10.1	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	120 Cr.	82.1	82.1/17.0	481	6.93	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,815.15 Cr	1,053.84		53.84	201.20	0.39%	16.35%	15.16%	6.10

All Competitor Stocks of Gujarat Terce Laboratories Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	11.90	12.89	10.72	12.03	13.02	12.21	11.89	13.30	12.68	12.32	10.85	12.93	12.29
Expenses	11.77	13.08	11.85	11.48	12.18	11.20	11.81	11.64	11.60	11.27	10.86	11.03	11.16
Operating Profit	0.13	-0.19	-1.13	0.55	0.84	1.01	0.08	1.66	1.08	1.05	-0.01	1.90	1.13
OPM %	1.09%	-1.47%	-10.54%	4.57%	6.45%	8.27%	0.67%	12.48%	8.52%	8.52%	-0.09%	14.69%	9.19%
Other Income	0.08	0.10	0.08	0.08	0.08	0.08	0.07	0.08	0.07	0.09	0.09	0.05	0.13
Interest	0.14	0.17	0.17	0.20	0.16	0.15	0.13	0.13	0.08	0.07	0.05	0.07	0.04
Depreciation	0.07	0.16	0.09	0.09	0.09	0.09	0.09	0.09	0.10	0.10	0.10	0.10	0.10
Profit before tax	0.00	-0.42	-1.31	0.34	0.67	0.85	-0.07	1.52	0.97	0.97	-0.07	1.78	1.12
Tax %		-290.48%	0.00%	0.00%	0.00%	35.29%	14.29%	1.97%	-3.09%	449.48%	-42.86%	21.35%	33.04%
Net Profit	0.00	0.80	-1.31	0.33	0.67	0.54	-0.08	1.48	1.01	-3.39	-0.04	1.40	0.76
EPS in Rs	0.00	1.08	-1.77	0.44	0.90	0.73	-0.11	1.99	1.36	-4.57	-0.05	1.89	0.98

Last Updated: March 3, 2026, 9:22 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 6:50 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	28.84	26.48	25.00	25.29	29.01	31.03	37.54	25.18	40.13	46.78	47.92	50.20	48.39
Expenses	27.89	25.70	24.84	25.21	28.68	30.54	36.86	27.77	39.02	48.94	46.65	46.31	44.32
Operating Profit	0.95	0.78	0.16	0.08	0.33	0.49	0.68	-2.59	1.11	-2.16	1.27	3.89	4.07
OPM %	3.29%	2.95%	0.64%	0.32%	1.14%	1.58%	1.81%	-10.29%	2.77%	-4.62%	2.65%	7.75%	8.41%
Other Income	0.13	0.08	0.19	0.44	0.41	0.32	0.29	0.62	0.31	0.35	0.32	0.31	0.36
Interest	0.41	0.41	0.38	0.31	0.23	0.25	0.29	0.39	0.40	0.72	0.68	0.42	0.23
Depreciation	0.33	0.16	0.19	0.19	0.19	0.21	0.24	0.18	0.28	0.36	0.37	0.38	0.40
Profit before tax	0.34	0.29	-0.22	0.02	0.32	0.35	0.44	-2.54	0.74	-2.89	0.54	3.40	3.80
Tax %	29.41%	72.41%	209.09%	150.00%	15.62%	-25.71%	36.36%	-0.39%	-17.57%	-42.21%	55.56%	128.53%
Net Profit	0.24	0.09	-0.67	-0.01	0.27	0.43	0.28	-2.52	0.87	-1.67	0.24	-0.98	-1.27
EPS in Rs	0.32	0.12	-0.90	-0.01	0.36	0.58	0.38	-3.40	1.17	-2.25	0.32	-1.32	-1.75
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-62.50%	-844.44%	98.51%	2800.00%	59.26%	-34.88%	-1000.00%	134.52%	-291.95%	114.37%	-508.33%
Change in YoY Net Profit Growth (%)	0.00%	-781.94%	942.95%	2701.49%	-2740.74%	-94.14%	-965.12%	1134.52%	-426.48%	406.33%	-622.70%

Gujarat Terce Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: December 4, 2025, 3:00 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42
Reserves	3.52	3.61	2.94	2.64	2.98	3.41	3.69	0.24	1.11	-0.56	-0.31	-0.94	0.42
Borrowings	8.74	8.21	7.13	7.00	0.37	0.68	2.60	4.74	6.67	7.27	3.87	0.94	0.60
Other Liabilities	6.24	7.06	6.98	6.59	8.69	7.94	8.80	9.47	12.19	14.39	12.29	15.41	15.99
Total Liabilities	25.92	26.30	24.47	23.65	19.46	19.45	22.51	21.87	27.39	28.52	23.27	22.83	24.43
Fixed Assets	6.13	6.48	6.34	6.17	1.88	2.06	2.29	2.45	4.29	3.99	3.69	3.65	3.47
CWIP	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.30	0.30	0.24	0.27	0.29	0.27	0.27	0.27	0.27	0.27	0.52	2.62
Other Assets	19.77	19.52	17.83	17.24	17.31	17.10	19.95	19.15	22.83	24.26	19.31	18.66	18.34
Total Assets	25.92	26.30	24.47	23.65	19.46	19.45	22.51	21.87	27.39	28.52	23.27	22.83	24.43

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	0.46	1.38	0.16	0.24	4.58	-0.61	-1.59	-0.16	-0.44	0.03	2.60	3.06
Cash from Investing Activity +	-0.27	0.08	-0.13	0.18	1.11	-0.13	-0.27	-0.42	-0.87	0.62	-0.46	0.46
Cash from Financing Activity +	-0.74	-0.73	-1.43	-0.36	-5.39	0.20	1.72	1.83	1.53	-0.12	-4.08	-2.83
Net Cash Flow	-0.55	0.73	-1.39	0.06	0.29	-0.55	-0.14	1.24	0.22	0.52	-1.94	0.69
Free Cash Flow	0.30	0.92	0.10	0.23	4.45	-1.01	-2.07	-0.66	-2.55	-0.03	2.53	3.41
CFO/OP	48%	191%	406%	688%	1,418%	-98%	-219%	0%	-31%	-3%	205%	81%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-7.79	-7.43	-6.97	-6.92	-0.04	-0.19	-1.92	-7.33	-5.56	-9.43	-2.60	2.95

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	116.56	126.81	123.81	114.31	57.62	53.29	68.16	74.94	49.75	62.34	43.11	36.86
Inventory Days	112.27	142.73	162.86	150.01	126.33	114.69	90.00	136.65	153.90	83.56	81.09	71.03
Days Payable	58.79	88.41	92.30	59.70	110.67	85.26	83.44	104.13	96.22	110.35	97.39	69.87
Cash Conversion Cycle	170.04	181.14	194.37	204.61	73.29	82.72	74.72	107.46	107.43	35.56	26.81	38.02
Working Capital Days	93.78	97.04	110.52	86.74	20.89	27.88	25.18	-14.06	6.82	-20.21	-7.69	-13.89
ROCE %	3.80%	3.39%	0.87%	1.91%	2.95%	5.39%	5.79%	-15.09%	8.26%	-14.80%	9.72%	41.41%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	36.45%	36.65%	36.78%	37.01%	37.03%	37.03%	37.03%	37.03%	37.03%	37.03%	37.03%	40.03%
Public	63.54%	63.35%	63.22%	62.99%	62.97%	62.97%	62.97%	62.97%	62.99%	62.96%	62.97%	59.98%
No. of Shareholders	13,579	13,499	13,404	13,327	13,203	13,394	13,538	13,710	13,764	13,804	13,812	13,805

Shareholding Pattern Chart

No. of Shareholders

Gujarat Terce Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-1.32	0.33	-2.25	1.18	-3.40
Diluted EPS (Rs.)	-1.32	0.33	-2.25	1.18	-3.40
Cash EPS (Rs.)	-0.80	0.82	-1.76	1.55	-3.16
Book Value[Excl.RevalReserv]/Share (Rs.)	8.73	9.58	9.25	11.50	10.32
Book Value[Incl.RevalReserv]/Share (Rs.)	8.73	9.58	9.25	11.50	10.32
Revenue From Operations / Share (Rs.)	67.64	64.65	63.05	54.09	33.93
PBDIT / Share (Rs.)	5.65	2.14	-2.44	1.92	-2.65
PBIT / Share (Rs.)	5.13	1.64	-2.93	1.55	-2.89
PBT / Share (Rs.)	4.57	0.73	-3.90	1.01	-3.41
Net Profit / Share (Rs.)	-1.32	0.32	-2.25	1.18	-3.40
PBDIT Margin (%)	8.34	3.30	-3.86	3.54	-7.80
PBIT Margin (%)	7.58	2.54	-4.64	2.85	-8.50
PBT Margin (%)	6.75	1.13	-6.18	1.86	-10.05
Net Profit Margin (%)	-1.94	0.50	-3.57	2.17	-10.00
Return on Networth / Equity (%)	-15.10	3.42	-24.35	10.22	-32.89
Return on Capital Employeed (%)	37.36	10.95	-18.22	8.09	-21.08
Return On Assets (%)	-4.28	1.04	-5.85	3.18	-11.55
Long Term Debt / Equity (X)	0.04	0.13	0.21	0.26	0.05
Total Debt / Equity (X)	0.14	0.54	1.06	0.78	0.59
Asset Turnover Ratio (%)	2.18	1.85	1.67	1.63	1.14
Current Ratio (X)	0.95	0.92	0.96	1.17	1.03
Quick Ratio (X)	0.66	0.59	0.69	0.68	0.70
Inventory Turnover Ratio (X)	13.10	1.80	1.11	1.40	0.95
Interest Coverage Ratio (X)	10.09	2.35	-2.51	3.55	-5.05
Interest Coverage Ratio (Post Tax) (X)	-1.36	1.36	-1.32	3.18	-5.47
Enterprise Value (Cr.)	45.53	43.07	17.60	26.07	8.45
EV / Net Operating Revenue (X)	0.90	0.89	0.37	0.64	0.33
EV / EBITDA (X)	10.87	27.12	-9.74	18.31	-4.30
MarketCap / Net Operating Revenue (X)	0.90	0.81	0.26	0.48	0.20
Price / BV (X)	7.00	5.53	1.80	2.27	0.67
Price / Net Operating Revenue (X)	0.90	0.81	0.26	0.48	0.20
EarningsYield	-0.02	0.01	-0.13	0.04	-0.48

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Gujarat Terce Laboratories Ltd. is a Public Limited Listed company incorporated on 28/03/1985 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ1985PLC007753 and registration number is 007753. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 50.20 Cr. and Equity Capital is Rs. 7.42 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	122/2, Ravi Estate, Gandhinagar District Gujarat 382729	Contact not found

Management
Name	Position Held
Mr. Natwarbhai P Prajapati	Chairman
Mr. Amrutbhai P Prajapati	Whole Time Director
Mr. Aalap Prajapat	Managing Director & CEO
Mrs. Chhayaben A Shah	Independent Director
Mr. Viplav S Khamar	Independent Director
Mr. Surendra Kumar Sharma	Independent Director
Mr. Navinchandra Patel	Independent Director

FAQ

What is the intrinsic value of Gujarat Terce Laboratories Ltd and is it undervalued?

As of 19 April 2026, Gujarat Terce Laboratories Ltd's intrinsic value is ₹24.05, which is 26.00% lower than the current market price of ₹32.50, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (14.6 %), book value (₹10.1), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd is trading at ₹32.50 as of 19 April 2026, with a FY2026-2027 high of ₹68.4 and low of ₹29.0. The stock is currently near its 52-week low. Market cap stands at ₹25.3 Cr..

How does Gujarat Terce Laboratories Ltd's P/E ratio compare to its industry?

Gujarat Terce Laboratories Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Gujarat Terce Laboratories Ltd financially healthy?

Key indicators for Gujarat Terce Laboratories Ltd: ROCE of 41.4 % indicates efficient capital utilization. Dividend yield is 0.00 %.

Is Gujarat Terce Laboratories Ltd profitable and how is the profit trend?

Gujarat Terce Laboratories Ltd reported a net profit of ₹-1 Cr in Mar 2025 on revenue of ₹50 Cr. Compared to ₹1 Cr in Mar 2022, the net profit shows a declining trend.

Does Gujarat Terce Laboratories Ltd pay dividends?

Gujarat Terce Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹32.50. The company is currently not paying meaningful dividends.